Novo Nordisk weight loss pill faces price war test
Novo Nordisk reports earnings as investors weigh if pill demand can offset falling prices. Early U.S. prescriptions beat forecasts despite rising competition.
Xurve View
洞察:
Xurve View
Novo Nordisk A/S-B faces a price war as 721,000 first-quarter prescriptions for its weight-loss pill meet intensifying competition from Eli Lilly & CO. The Denmark-based drugmaker has lost $400B in market value since its 2024 peak following disappointing clinical trials. Investors need proof that high volumes can offset falling prices in the United States obesity market.
